Intuitive Surgical delivered a strong finish to 2025, with full-year revenue growing 21% to $10.1 billion and procedures increasing 19% to over 3.1 million. Pro forma EPS rose 22%, marking the third consecutive year of above-20% growth, while free cash flow surged to $2.5 billion. Growth was driven by robust adoption of the da Vinci 5 (870 systems placed in 2025), a 51% increase in Ion procedures, and 87% growth in single-port procedures. Looking ahead to 2026, the company forecasts procedure growth of 13-15% but anticipates gross margin pressure (67-68%) due to a 120-basis-point impact from tariffs and a higher mix of newer platforms like da Vinci 5 and Ion.
| Metric | Value | Change |
|---|---|---|
| Q4 Revenue | $2.87 billion | +19% |
| FY 2025 Revenue | $10.1 billion | +21% |
| Q4 Pro Forma EPS | $2.53 | +14.5% |
| FY 2025 Procedures | 3.1 Million | +18% |
| Q4 Gross Margin | 67.8% | -170 bps YoY |
| da Vinci 5 Placements (2025) | 870 | N/A |
| Free Cash Flow (2025) | $2.5 billion | +92% |
da Vinci 5 Cycle and Mix Shift: The strategic shift to the da Vinci 5 platform is accelerating, with 870 systems placed in 2025 (303 in Q4). This drives higher average selling prices ($1.68M in Q4 vs $1.6M prior year) and increases recurring revenue through the 'My Intuitive+' digital subscription. However, management noted that da Vinci 5 is 'not yet at target product costs,' creating a near-term headwind to gross margins despite the strategic imperative of standardizing on the new platform.
ASC Expansion with XiR: Intuitive is strategically targeting the Ambulatory Surgery Center (ASC) market by refurbishing older Xi systems (XiR). With 42 XiR systems placed in 2025, this initiative aims to capture lower-acuity, higher-volume procedures like hernia repair and cholecystectomy. Management estimates that 70% of the ASC opportunity is within existing IDN customers, allowing them to leverage current relationships and slide older systems into lower-cost settings of care.
Entry into Cardiac Surgery: The company received FDA clearance for non-Force Feedback cardiac instruments on da Vinci 5, opening a new vertical estimated at 160,000 procedures annually in cleared regions. While management is bullish on the long-term potential to improve cardiac outcomes, they committed to a 'measured rollout' in 2026, focusing on training and education to ensure clinical quality in this complex new disease state.
International Growth and China Dynamics: International procedure growth remains a key driver, growing 23% year-over-year and now accounting for 35% of global procedures. However, the strategic landscape in China is shifting, with management noting 'intensified' robotic competition and provincial tenders favoring local suppliers. Intuitive is responding by leveraging local manufacturing and competing on value, though this creates a competitive risk factor for 2026.
Gross Margin Compression: Pro forma gross margin declined to 67.8% in Q4 from 69.5% in the prior year, driven by a 95-basis-point impact from tariffs and a higher mix of lower-margin da Vinci 5 and Ion revenue. Guidance for 2026 assumes a further 120-basis-point impact from tariffs, suggesting margin pressure will persist as the company scales newer, cost-heavy platforms.
Competitive Pressure in China: Management acknowledged that 'robotic competition in China intensified in Q4,' noting that provincial tenders are expressing a preference for local suppliers. This led to a lower win ratio in the quarter. As China is a critical growth market, increased local competition and pricing pressure could dampen capital placement growth in the region.
Japan Capital Headwinds: Procedure growth in Japan lagged expectations due to government budget challenges. While reimbursement changes are expected in June 2026, the near-term capital environment remains difficult, potentially limiting system placements and procedure growth in the near term.
Cardiac Adoption Uncertainty: While the FDA clearance for cardiac procedures is a positive milestone, management emphasized a 'measured rollout' due to the complexity of the procedures. This suggests that revenue contribution from this new vertical will be slow to materialize and requires significant investment in training infrastructure before scaling.
Overall: Management displayed a confident and disciplined demeanor, emphasizing the company's position in the 'early stages' of a long-term growth journey while acknowledging specific execution risks. They were notably measured regarding the rollout of new cardiac capabilities but expressed strong conviction in the core da Vinci 5 adoption and international expansion.
Confidence: HIGH - Management provided specific guidance ranges, detailed operational metrics, and articulated clear strategies for headwinds like tariffs and ASC expansion. Their language was forward-looking yet grounded in data.
13% to 15%
67% to 68% of net revenue
11% to 15%
22% to 23%
Hedging & Uncertainty: Management frequently used temporal and probabilistic hedges to set expectations for the new cardiac and ASC initiatives. Phrases like 'measured rollout,' 'early stages,' and 'multiyear efforts' were used to temper immediate revenue expectations for long-term strategic bets. They also hedged guidance by citing 'potential impact' from macro factors like ACA subsidies and Medicaid funding, stating, 'This range considers the potential impact of changes to ACA premium subsidies.' This suggests a cautious approach to forecasting in an uncertain macro environment.
We continue to believe we are in the early stages of this journey. - David Rosa, CEO
Given the complexity of minimally invasive cardiac surgery, we are planning a measured rollout to support training, education and adoption. - David Rosa, CEO
Robotic competition in China intensified in Q4, where we saw provincial tenders express preference for local suppliers. - Jamie Samath, CFO
We believe deeply that patients requiring cardiac surgery can benefit from a minimally invasive approach with da Vinci. - David Rosa, CEO
We expect the proportion of systems placed under operating lease arrangements to increase, primarily driven by OUS customers. - Jamie Samath, CFO
Analyst Sentiment: Analysts were highly inquisitive about the new cardiac clearance and the mechanics of the ASC expansion strategy, reflecting interest in new growth vectors. Questions also probed the sustainability of margins amidst tariff headwinds and rising competition in China.
Management Responses: Management provided detailed, data-driven responses, particularly breaking down the cardiac TAM (160k procedures) and the economic logic of the XiR strategy for ASCs. They were transparent about the 'measured' pace of cardiac adoption and the specific impact of tariffs on margins.
Cardiac Surgery Opportunity: Analysts sought clarity on the FDA clearance and the commercial opportunity. Management outlined a 160,000 procedure opportunity in cleared regions but emphasized a slow, training-focused rollout.
ASC and XiR Strategy: Discussion focused on how the refurbished Xi systems fit into the ASC economic model. Management explained that 70% of the opportunity is with existing IDNs and that current utilization in ASCs is healthy.
Margin Headwinds: Analysts asked about gross margin assumptions. Management detailed the offsetting factors of tariffs (120bps impact), product cost reductions, and the unfavorable mix of da Vinci 5/Ion.
Intuitive Surgical remains a premier growth story in MedTech, successfully executing the da Vinci 5 upgrade cycle while expanding into new verticals like cardiac and lung biopsy (Ion). The 13-15% procedure growth guidance for 2026 demonstrates resilience despite macro headwinds. While margins face pressure from tariffs and product mix, the shift to recurring revenue via 'My Intuitive+' and the expansion into ASCs via XiR provide multiple levers for long-term value creation. The company's strong cash generation ($2.5B) and share repurchase program further underscore shareholder-friendly capital deployment.
Management cited a 95-basis-point impact from tariffs in Q4 and expects a 120-basis-point impact in 2026, representing a persistent cost headwind that requires offsetting actions.
Competition intensified in China with tenders favoring local suppliers, impacting Intuitive's win ratio in Q4 despite local manufacturing efforts.
The shift of procedures from hospitals to Ambulatory Surgery Centers (ASCs) is accelerating, driven by payer reimbursement dynamics, which Intuitive is capitalizing on via its XiR strategy.
Capital pressure in Japan is dampening growth, though new reimbursement for robotic procedures is expected in June 2026.